Dutch Biologic Monitor: Fatigue Among Biologic Recipients Across a Range of Immune-Mediated Inflammatory Diseases

June 3-6, 2020; Virtual Meeting
Overall, 7% of adults self-reported biologic-associated fatigue. Compared with patients not reporting fatigue, they were younger and more frequently smoked, were more likely to have Crohn disease, and used infliximab, rituximab, or vedolizumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 205 KB
Released: August 13, 2020


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

CCO slides: current best practice for choosing among biologics and other JAK inhibitors for patients with moderate to severe ulcerative colitis

Released: November 13, 2020

Expert video from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Released: November 13, 2020 Expired: November 12, 2021

Pooled analysis of filgotinib trials in rheumatoid arthritis presented at ACR 2020 finds low incidence of VTE and MACE regardless of dose, by CCO

Released: November 13, 2020

ACR 2020: ARCTIC REWIND on flare risk of TNF inhibitor taper and withdrawal among patients with rheumatoid arthritis (RA) and stable remission, as reported by CCO

Released: November 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.